
Keywords: AVD; aortic valve disease; βGP; beta-glycerophosphate; HAS; hyaluronan synthase; HYAL; hyaluronidase; IαI; Inter-alpha-Inhibitor; MAPK; mitogen-activated protein kinase; PDMS; polydimethylsiloxane; RHAMM; the receptor for hyaluronan mediated motility; T